Spinal muscular atrophy (SMA) is an inherited disorder caused by homozygous deletions or variants in the SMN1 gene. As a consequence of absent or low levels of SMN1 protein, the motor neurons in spinal cord degenerate, resulting in atrophy of the voluntary muscles of the limbs and trunk. Nusinersen is a synthetic antisense oligonucleotide designed to bind to a specific sequence in exon 7 of the SMN2 transcript causing the inclusion of exon 7 in the SMN2 transcript, leading to production of full length functional SMN2 protein, which is very similar to SMN1.

This policy is applicable to BlueCHiP for Medicare products only. For Commercial Products, see related policy section.

**MEDICAL CRITERIA**

**BlueCHiP for Medicare**

**Initial Evaluation**

Spinraza (nusinersen) will be approved when ALL of the following are met:

1. ONE of the following:
   a. There is documentation that the patient is currently being treated with the requested agent for an FDA approved indication
   OR
   b. The patient has a diagnosis of Spinal Muscular Atrophy (SMA) type I (Werdnig-Hoffmann disease) or type II AND ALL of the following:
      1. The prescriber has provided documentation of genetic testing confirming the patient has ONE of the following:
         i. Homozygous deletion of SMN1 gene
         OR
         ii. Homozygous absence of SMN1 gene due to gene conversion (i.e. SMN1 gene conversion to SMN2 gene)
         OR
         iii. Compound heterozygote mutation of SMN1 gene
   AND

2. The prescriber has provided documentation confirming the patient has two or more copies of SMN2 gene as determined by genetic testing
   AND

3. The prescriber has provided documentation indicating the patient had onset of SMA symptoms at or before 18 months of age
   AND

The requested agent is prescribed by a prescriber (e.g. neurologist, geneticist) that specializes in the diagnosis and management of SMA or in consultation with a prescriber that specializes in the diagnosis and management of SMA AND

2. The requested dose is within FDA approved labeling
   AND

The patient does not have any FDA labeled contraindications to therapy with the requested agent.
Length of Approval:
Up to 6 months. **NOTE:** For patients initiating therapy, approval will include 4 initial loading doses and 1 maintenance dose for the remainder of the 6 months.

Renewal Evaluation
Spinraza (nusinersen) will be approved for continued use when ALL of the following are met:
1. The patient was previously approved
   AND
   a. The prescriber has provided documentation indicating the patient has had disease stabilization or clinical improvement in the symptoms* of SMA (*e.g. motor function, limb and trunk weakness, hypotonia and impaired head control, difficulty breathing, swallowing, feeding, and handling secretions etc)
   AND
   b. The patient does not have any FDA labeled contraindications to therapy with the requested agent
   AND
   c. The requested agent is prescribed by a prescriber (e.g. neurologist, geneticist) that specializes in the diagnosis and management of SMA or in consultation with a prescriber that specializes in the diagnosis and management of SMA
   AND
   d. The requested dose is within FDA approved labeling

Length of Approval: Up to 12 months

**PRIOR AUTHORIZATION**
Prior authorization is required for BlueCHiP for Medicare

**POLICY STATEMENT**
Spinrava (Nusinersen) may be considered medically necessary when the medical criteria are met.

**COVERAGE**
Benefits may vary between groups and contracts. Please refer to the appropriate Evidence of Coverage for applicable not medically necessary services.

**BACKGROUND**
Spinal Muscular Atrophy1-6,8
Spinal Muscular Atrophy (SMA) is an autosomal recessive genetic disease characterized by muscle weakness and atrophy due to degeneration of spinal motor neurons. It is the second most common fatal autosomal recessive disorder after cystic fibrosis. It affects approximately 1 in 6000 to 10,000 live births. SMA occurs as a result of deletion or mutation of the survival motor neuron 1 (SMN1) gene which codes for the SMN protein. The consequence of absent or non-functional SMN1 protein is degeneration of the motor neurons resulting in atrophy of the voluntary muscles of the limbs and trunk. A second gene, SMN2, is also capable of coding for the SMN protein. However, SMN2 frequently leads to production of a truncated SMN protein that is dysfunctional and easily degraded. Nusinersen, an antisense oligonucleotide, binds to SMN2 thereby promoting production of higher levels of functional SMN protein.

Current literature indicates the number of SMN2 gene copies generally correlates with SMA phenotypes such that the higher the number of SMN2 gene copies, the milder the disease.

Patients suspected of having SMA should have the diagnosis confirmed by genetic testing. This is often done by a neurologist or geneticist. A positive diagnosis can be made if the patient is found to have homozygous deletion or conversion of SMN1 gene to SMN2 gene. 95% of SMA patients are diagnosed in this manner.
The remainder (3 – 5%) of SMA patients can have the diagnosis confirmed if found to have compound heterozygous mutation of SMN1 gene.

SMA can be classified into different types based on varying severity and age of onset. Type 0 is very rare while type 1 is the most common accounting for 60% to 70% SMA. Type II is less severe than type 0 and type I and accounts for 20% to 30% of SMA. Type III and IV are milder forms of SMA that together account for 10% to 20% of SMA.

### Clinical Classification of Spinal Muscular Atrophy

<table>
<thead>
<tr>
<th>SMA Type2,6</th>
<th>Age of Onset2,6</th>
<th>Usual # of SMN2 gene copies6</th>
<th>Characteristics2</th>
<th>Highest Function2,6</th>
<th>Natural Age of Death2</th>
</tr>
</thead>
<tbody>
<tr>
<td>Type 0 (severe)</td>
<td>Prenatal</td>
<td>1</td>
<td>Loss of fetal movement during later stages of pregnancy, little motor function at birth, inability to breath or swallow independently</td>
<td>None achieved</td>
<td>&lt; 6 months</td>
</tr>
<tr>
<td>Type 1* (severe)</td>
<td>0 – 6 months</td>
<td>2</td>
<td>Weakness and hypotonia, paradoxical breathing, difficulty swallowing, feeding, and handling secretions</td>
<td>Never sits</td>
<td>&lt; 2 years</td>
</tr>
<tr>
<td>Type 2 (intermediate)</td>
<td>7 – 18 months</td>
<td>2 – 4 (80% have 3 copies)</td>
<td>Bulbar weakness, difficulty swallowing, diaphragmatic breathing, difficulty clearing tracheal secretions, fine tremors</td>
<td>Never stands</td>
<td>&gt; 2 years</td>
</tr>
<tr>
<td>Type 3 (mild)</td>
<td>&gt; 18 months</td>
<td>80% have 4 copies</td>
<td>Muscle and joint aches, difficulty swallowing and coughing, hypoventilation, loss of ambulation, scoliosis</td>
<td>Stands and walks</td>
<td>Adult</td>
</tr>
<tr>
<td>Type 4 (adult)</td>
<td>Second or third decade</td>
<td>≥ 4</td>
<td>Mild motor impairment without respiratory or gastrointestinal problems</td>
<td>Walks during adult years</td>
<td>Adult</td>
</tr>
</tbody>
</table>

* Also referred to as Werdnig-Hoffmann disease3

Considering vast clinical presentation of SMA, patient care should be tailored to the specific patient needs and include respiratory support, physical therapy, and nutritional support.

**Nusinersen Safety1**
The most common adverse reactions in patients treated with nusinersen include lower respiratory infection, upper respiratory infection, and constipation. Nusinersen is associated with increased risk for bleeding complications and renal toxicity. It is therefore, recommended to obtain platelet count, coagulation laboratory levels, and quantitative spot urine protein level prior to each dose. Nusinersen does not have an FDA labeled contraindication.

**Nusinersen Efficacy1**
The efficacy of nusinersen, upon which its FDA approval was granted, is based on results of a double-blind, sham-procedure controlled trial (ENDEAR) in symptomatic infantile-onset SMA (type I) patients. Its efficacy was further supported by open-label trials conducted in pre-symptomatic and symptomatic SMA patients. Efficacy of nusinersen in patients with later-onset SMA was evaluated in a separate phase III clinical trial (CHERISH).

**ENDEAR1**
This was a phase III, double-blind, randomized, sham-procedure controlled study to assess efficacy, safety, and tolerability of nusinersen in patients with symptomatic infantile-onset SMA. Patients (n=121) were randomized 2:1 to receive either nusinersen or sham-procedure control. Key inclusion criteria included the following: onset of SMA symptoms before 6 months of age, age ≤ 7 months at the time of the first dose and two copies of the SMN2 gene. The primary outcome was proportion of responders (i.e. improvement in
motor milestones according to section 2 of the HINE) and was assessed at study day 183 and onwards. Treatment responders were defined as those with at least a 2 point increase in ability to kick, or at least a 1 point increase in the motor milestones of head control, rolling, sitting, crawling, standing or walking. An interim analysis of the results was evaluated among 82 patients who were eligible. A statistically significant percent of patients in the nusinersen arm achieved motor milestone response compared to those in the sham-procedure arm. The trial also assessed treatment effects using the CHOP-INTEND, a tool that evaluates motor skills in patients with infantile-onset SMA.

**Motor Milestone Response (HINE section 2) and CHOP-INTEND results**

<table>
<thead>
<tr>
<th>Endpoint</th>
<th>SPINRAZA-treated patients (n=52)</th>
<th>Sham-control patients (n=30)</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Motor Milestone (HINE Section 2)</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Achievement of a motor milestone response</td>
<td>21 (40%)</td>
<td>0 (0%)</td>
</tr>
<tr>
<td>p&lt;0.0001</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>CHOP-INTEND Improvement from Baseline</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>At least 4-points</td>
<td>33 (63%)</td>
<td>1 (3%)</td>
</tr>
<tr>
<td><strong>CHOP-INTEND Worsening from Baseline</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>At least 4-points</td>
<td>2 (4%)</td>
<td>12 (40%)</td>
</tr>
</tbody>
</table>

1Analyses included all subjects who were alive with the opportunity for at least a 6-month (Day 183) assessment and all subjects who died or withdrew from the study at the time of the interim analysis

CHERISH7,9,10

This was a phase III, double-blind, randomized, sham-procedure controlled study of nusinersen in patients with later-onset SMA consistent with type II SMA. Subjects were randomized to receive nusinersen (n=84) or a sham-procedure control (n=42). The trial enrolled patients with onset of SMA symptoms at greater than 6 months of age and all patients had symptom onset by 21 months. The patients were required to be able to sit independently and to have never had the ability to walk independently. The primary end point was change in baseline HFMSE score at 15 months. HFMSE is a tool used to assess motor function in children with SMA. Patients enrolled in the trial were required to have a baseline HFMSE score of ≥ 10 and ≤ 54. A change of ≥3 points in the HFMSE is estimated to represent a clinically meaningful improvement.

An interim analysis of the results at study month 15 was conducted among 54 patients who were eligible for the analysis. The results showed a statistically significant change from baseline in the HFMSE score in the nusinersen group (4.0 (95% CI: 2.9-5.1)) compared to the sham-procedure control group (-1.9 (95% CI: -3.8-0.0)) (p=0.0000002). In the end of study analysis, the treatment difference in change from baseline to Month 15 in mean HFMSE score also was highly clinically and statistically significant (4.9 points: nusinersen, 3.9-point improvement; sham procedure control, 1.0-point decline; nominal. P=.000000). There were no treatment discontinuations due to adverse events.

Based on the results of the interim analysis, the CHERISH trial was stopped. All participants could then elect to enroll in SHINE, an open-label trial evaluating the long term safety and tolerability of nusinersen. SHINE is ongoing at the time of this writing (February 2017). A second, ongoing trial (NURTURE), is evaluating efficacy and safety of nusinersen in pre-symptomatic infants genetically diagnosed with SMA.

**CODING**

Blue CHiP for Medicare

The following codes are covered when the criteria are met.

For claims filed with date of services 7/1/2017 and after
C9489 Injection, nusinersen, 0.1 mg

For claims filed with date of services 1/1/2018 and after
J2326 Injection, nusinersen, 0.1 mg
RELATED POLICIES
Prior Authorization of Drugs

PUBLISHED
Provider Update June 2018
Provider Update May 2017

REFERENCES: